Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,061 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y, Ji M, Jiang Y, Yin R, Wang Z, Li H, Wang S, He K, Ma Y, Wang Z, Lu J, Shi M, Shen B, Zhou G, Leong TL, Wang X, Chen C, Feng J. Shi Y, et al. Among authors: shi m. Transl Lung Cancer Res. 2022 Jun;11(6):1051-1068. doi: 10.21037/tlcr-22-350. Transl Lung Cancer Res. 2022. PMID: 35832459 Free PMC article.
[A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients].
Sun Y, Lin H, Zhu Y, Feng J, Chen Z, Li G, Zhang X, Zhang Z, Tang J, Shi M, Hao X, Han H. Sun Y, et al. Among authors: shi m. Zhongguo Fei Ai Za Zhi. 2006 Jun 20;9(3):254-8. doi: 10.3779/j.issn.1009-3419.2006.03.09. Zhongguo Fei Ai Za Zhi. 2006. PMID: 21172156 Free article. Chinese.
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
Zhao HY, Chen GY, Huang Y, Li XL, Feng JF, Shi MQ, Cheng Y, Ma LX, Zhang YP, Gu CP, Song XQ, Zhou D, Zhang L. Zhao HY, et al. Medicine (Baltimore). 2015 Jan;94(2):e249. doi: 10.1097/MD.0000000000000249. Medicine (Baltimore). 2015. PMID: 25590835 Free PMC article. Clinical Trial.
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, Chen G, Wu C, He J, Wu G, Song X, Gao J, Liu W, Li B, Shi J, Huang C, Yu J, Feng J, Yue H, Shi M, Xia J. Zhou C, et al. Among authors: shi m, shi j. Clin Lung Cancer. 2016 Mar;17(2):119-27. doi: 10.1016/j.cllc.2015.12.002. Epub 2015 Dec 17. Clin Lung Cancer. 2016. PMID: 26781346 Clinical Trial.
8,061 results